Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang Sells 1,500 Shares of Stock

Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 1,500 shares of Beigene stock in a transaction on Monday, November 18th. The stock was sold at an average price of $194.49, for a total transaction of $291,735.00. Following the transaction, the chief marketing officer now directly owns 291,667 shares in the company, valued at $56,726,314.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jane Huang also recently made the following trade(s):

  • On Monday, November 4th, Jane Huang sold 32,900 shares of Beigene stock. The stock was sold at an average price of $190.46, for a total transaction of $6,266,134.00.
  • On Tuesday, September 3rd, Jane Huang sold 2,862 shares of Beigene stock. The stock was sold at an average price of $144.45, for a total transaction of $413,415.90.

BGNE traded up $4.00 during trading on Thursday, hitting $207.31. The company had a trading volume of 5,362 shares, compared to its average volume of 331,776. The company has a market capitalization of $9.41 billion, a PE ratio of -17.08 and a beta of 1.00. Beigene Ltd has a one year low of $108.00 and a one year high of $208.40. The firm’s 50-day moving average price is $153.76 and its 200 day moving average price is $135.58. The company has a quick ratio of 5.26, a current ratio of 5.40 and a debt-to-equity ratio of 0.20.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($5.11) EPS for the quarter, missing the consensus estimate of ($3.56) by ($1.55). The company had revenue of $50.14 million during the quarter, compared to the consensus estimate of $65.43 million. Beigene had a negative net margin of 192.75% and a negative return on equity of 53.11%. The company’s revenue was down 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.53) earnings per share. Sell-side analysts forecast that Beigene Ltd will post -12.52 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Marshall Wace North America L.P. bought a new position in shares of Beigene in the first quarter worth $76,000. Amundi Pioneer Asset Management Inc. boosted its position in shares of Beigene by 9.7% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 17,001 shares of the company’s stock worth $2,244,000 after acquiring an additional 1,500 shares in the last quarter. NN Investment Partners Holdings N.V. acquired a new stake in shares of Beigene during the 2nd quarter worth approximately $1,066,000. Livforsakringsbolaget Skandia Omsesidigt increased its stake in Beigene by 17.3% in the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 9,500 shares of the company’s stock valued at $1,178,000 after acquiring an additional 1,400 shares during the last quarter. Finally, FDx Advisors Inc. acquired a new position in Beigene during the second quarter valued at approximately $205,000.

A number of equities analysts have recently weighed in on BGNE shares. Bank of America reissued a “buy” rating and set a $230.00 price target on shares of Beigene in a research report on Monday. BidaskClub raised shares of Beigene from a “hold” rating to a “buy” rating in a research report on Tuesday, October 22nd. JPMorgan Chase & Co. set a $215.00 price target on shares of Beigene and gave the stock a “buy” rating in a research report on Monday, November 4th. Zacks Investment Research cut shares of Beigene from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley reduced their price target on shares of Beigene from $201.00 to $200.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the stock. Beigene has an average rating of “Buy” and an average target price of $208.00.

Beigene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Recommended Story: Limitations of analyzing profit margin

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.